NCT02797249 (APPEC) is a Phase 3 clinical trial of Aspirin in Preeclampsia, sponsored by Peking University First Hospital.

Who is sponsoring NCT02797249?

NCT02797249 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT02797249?

Interventions in NCT02797249: Aspirin, Blank.

What condition does NCT02797249 study?

NCT02797249 studies Preeclampsia.

Is NCT02797249 still recruiting?

NCT02797249 is currently completed. Last updated 1 May 2019.

Last reviewed 2019-05-01 · How we verify

NCT02797249: APPEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low Dose Aspirin in the Prevention of Preeclampsia in China

Completed Phase 3 Last updated 1 May 2019

What this trial tests

Phase 3 trial testing Aspirin in Preeclampsia in 1,000 participants. Completed in 30 March 2019.

Timeline

7 December 2016

Primary endpoint
19 January 2019

30 March 2019

Quick facts

Lead sponsor	Peking University First Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	1,000
Start date	7 December 2016
Primary completion	19 January 2019
Estimated completion	30 March 2019
Sites	1 location across China

Drugs / interventions tested

Aspirin — full drug profile →
Blank

Conditions studied

Preeclampsia — all drugs for Preeclampsia →

Sponsor

Peking University First Hospital

Who can join

Adults 18 to 55, female only, with Preeclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin in Chinese pregnant women, starting between 12+ and 20 weeks of pregnancy, based on clinical characteristics aiming to reduce the incidence of preeclampsia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension.
Huai J, Lin L, Juan J, Chen J, et al · · 2021 · cited 29× · PMID 33400389 · DOI 10.1111/jch.14149
Low-dose aspirin in the prevention of pre-eclampsia in China (APPEC study): protocol for a multicentre randomized controlled trial.
Lin L, Zhu Y, Li B, Yang H, et al · · 2018 · cited 10× · PMID 30400937 · DOI 10.1186/s13063-018-2970-3

Verify or expand the search:

Other trials of Aspirin

Trials testing the same drug.

NCT07525635 — Aspirin Dosing in Pregnancy · EARLY_PHASE1 · not yet recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
NCT07373756 — Randomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk · Phase 4 · not yet recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06638151 — Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) · Phase 2 · recruiting

Other recruiting trials for Preeclampsia

Currently open trials in the same condition.

NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02797249 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 1 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02797249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing